Eortc Qlq-C30 (Qlq-C30) Symptoms In Patients (Pts) With Her2-Negative Metastatic Breast Cancer (Mbc) And A Germline Brca Mutation (Gbrcam) Receiving Olaparib Vs Chemotherapy Treatment Of Physician'S Choice (Tpc) In Olympiad

1045Background: In the Phase III OlympiAD study, pts with HER2-negative mBC and a gBRCAm who received olaparib vs TPC showed statistically significant and clinically meaningful benefit in progression-free survival (NCT02000622; Robson et al. NEJM 2017). Global health status/quality of life also favored olaparib. This analysis reports the impact of treatment on symptoms using the QLQ-C30 questionnaire. Methods: Pts were randomized (open label) to olaparib tablet monotherapy or single-agent TPC (capecitabine, vinorelbine or eribulin). QLQ-C30, completed by patients at baseline and every 6 weeks until disease progression, evaluated three multi-item symptom scales and five single items (common cancer symptoms). Symptoms were scored on a 0 to 100 scale (higher scores indicated worse symptoms). Statistical analysis included clinically meaningful improvement (reduction in score of ≥10 points) and adjusted mean change from baseline scores. Results: Overall questionnaire compliance rates were 93.2% for olaparib an...